MGMT and glioblastoma: Results show that our multiparametric radiogenomic model incorporating patient’s age, texture features from baseline MRI, and MGMT methylation status can predict longer survival (≥18 months) in patients with IDH-wildtype, WHO grade 4 GBM at the time of diagnosis with an accuracy of 73.5% in the training cohort and 89.3% in the external validation cohort.